Topical verapamil is a skin-applied formulation of a drug originally designed to treat heart conditions, repurposed for a very different job: softening scars, shrinking keloids, and possibly treating fibrotic conditions like Peyronie’s disease. Verapamil belongs to a class of medications called calcium channel blockers, and when applied to the skin rather than swallowed, it appears to interfere with the overproduction of collagen that makes scars thick and raised. The evidence behind it is genuinely promising in some areas and frustratingly thin in others, and the question of whether the drug can actually reach its target tissue through the skin remains one of the more contested issues in dermatology and urology.
How Verapamil Works on Scars
Scarring goes wrong when the body overshoots its wound-repair response. Fibroblasts, the cells responsible for laying down collagen during healing, keep producing scar tissue long after the wound has closed. In keloids and hypertrophic scars, this process spirals, leaving raised, firm masses of collagen that can be painful, itchy, and cosmetically distressing. Verapamil tamps down this overproduction through several pathways at once.
At the cellular level, calcium channel blockers like verapamil reduce the amount of type I and type III collagen that fibroblasts deposit into the tissue surrounding them. They also boost the activity of enzymes that break collagen down, shifting the balance away from accumulation and toward remodeling.1PubMed. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix In animal studies, verapamil applied to nerve-injury sites led to visibly less collagen buildup compared with untreated controls, with measurably lower levels of both type I and type III collagen protein.2PubMed Central. Verapamil inhibits scar formation after peripheral nerve repair in vivo
Verapamil also lowers the output of signaling molecules that drive scar formation. When researchers treated keloid fibroblasts with verapamil, they found significant drops in interleukin-6 and vascular endothelial growth factor, two molecules that promote inflammation and blood-vessel growth in scar tissue.3Journal of Urology. Effects of the calcium antagonist verapamil on interleukin-6 and vascular endothelial growth factor production in human keloid fibroblasts In a silicone-gel formulation, adding verapamil at various concentrations led to significantly fewer fibroblasts in the treated tissue compared with silicone alone.4PubMed Central. Verapamil‐containing silicone gel reduces scar hypertrophy The combined effect is a quieter wound-healing environment: less collagen production, more collagen breakdown, fewer inflammatory signals, and fewer of the cells driving the whole process.
Evidence for Keloid and Hypertrophic Scar Treatment
The standard treatment for keloids and hypertrophic scars has long been injecting corticosteroids directly into the scar tissue. It works, but the injections hurt, and repeated steroid exposure can thin the surrounding skin and cause discoloration. Verapamil has attracted attention as a gentler alternative, and the clinical data suggests it performs in roughly the same range as corticosteroids for this purpose.
A systematic review of the available studies found that verapamil could improve keloid and hypertrophic scars and was not significantly different from conventional corticosteroid injections in the studies examined. Adverse effects were few. The review’s authors did flag that most of the included studies had a high risk of bias due to issues with randomization and blinding, which means the results should be taken with some caution.5PubMed Central. Role of verapamil in preventing and treating hypertrophic scars and keloids That caveat matters: when trial quality is uneven, a treatment can look better in the data than it performs in the real world. Still, the consistency of the direction of the findings across multiple studies is encouraging.
Verapamil has also been studied as a preventive measure rather than a reactive treatment. One clinical investigation using verapamil at a concentration of 50 micromolar found it effective as a scar modulator after plastic surgery, concluding that its use could help avoid the development of keloids and hypertrophic scars in the first place.6PubMed. Topical verapamil as a scar modulator For people who know they are prone to keloid formation, applying a verapamil-based formulation during the healing window may offer a way to head off the problem rather than treating it after the scar has already formed.
The Peyronie’s Disease Controversy
Peyronie’s disease involves a fibrous plaque forming inside the tunica albuginea, the tough sheath surrounding the erectile tissue of the penis. The plaque causes curvature, pain, and often considerable distress. Because the plaque is essentially scar tissue, and because verapamil has shown anti-fibrotic properties, clinicians have experimented with both injected and topical verapamil for this condition.
A pilot study of topical verapamil applied to the penile shaft reported striking results: after nine months, over 94% of patients experienced improvement in curvature, with an average curvature change of about 61%. Plaque size also shrank substantially.7PubMed. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie’s disease–a placebo-controlled pilot study Those numbers sound extraordinary, and they have been widely cited by companies marketing topical verapamil products for Peyronie’s.
The problem is that a separate study directly tested whether verapamil gel applied to the penile skin actually reaches the tunica albuginea. It did not. Researchers found a small amount of verapamil in the urine, indicating some systemic absorption through the skin, but no verapamil whatsoever was detected in any tunical tissue specimens.8Journal of Urology. Transdermal Application of Verapamil Gel to the Penile Shaft Fails to Infiltrate the Tunica Albuginea If the drug cannot physically reach the plaque, it is hard to explain how it could shrink it.
This creates one of the more frustrating contradictions in the field. Some clinicians and patients report meaningful improvement, while the pharmacokinetic evidence suggests the drug is not getting where it needs to go. Several possible explanations have been offered: the drug might exert indirect effects through nearby tissues, the positive results might reflect natural disease fluctuation or placebo response, or the penetration study’s methodology might not have captured drug levels in the exact tissue layer where the plaque sits. The American Urological Association has generally recommended intralesional injection of verapamil over topical application for Peyronie’s, reflecting skepticism about skin-applied formulations for this particular condition.
Why Getting Through the Skin Is the Central Challenge
The penetration problem with Peyronie’s disease is really just an extreme version of a challenge that affects all topical verapamil applications. Skin is a remarkably effective barrier. The outermost layer, the stratum corneum, is designed to keep molecules out, and verapamil is a fairly large, lipophilic molecule that does not cross that barrier easily in therapeutic concentrations.
Researchers have been working on formulation strategies to solve this. One approach involves loading verapamil into niosomes, which are tiny vesicles made from non-ionic surfactants that can fuse with skin cells and deliver their cargo deeper into tissue. A niosomal gel formulation showed improved permeation and synergistic effects in preclinical testing, suggesting better safety and efficacy for long-term treatment of hypertrophic scars.9PubMed. Repurposing verapamil hydrochloride with niosomal gel technology: Enhanced efficacy and skin penetration in hypertrophic scars Another strategy that has shown promise in laboratory testing is embedding verapamil in a silicone gel matrix, which not only delivers the drug but also provides the occlusive, hydrating environment that silicone sheeting already provides for scar management.10PubMed Central. Verapamil‐containing silicone gel reduces scar hypertrophy
The formulation you choose matters more than you might expect. A generic verapamil cream compounded at a local pharmacy may have very different penetration characteristics than a purpose-designed niosomal or silicone-based product. This is one reason clinical results vary so widely across studies: the “topical verapamil” used in one trial may deliver the drug quite differently from the version used in another. If you are considering topical verapamil for scar treatment, the specific product formulation is worth asking about.
Combining Topical Verapamil with Energy-Based Devices
One of the more active areas of research involves using lasers and other energy devices to punch temporary micro-channels through the skin’s barrier, then applying verapamil so it can reach deeper tissue layers it would otherwise never penetrate. Fractional lasers, micro-plasma radiofrequency, and ultrasound have all been studied as tools to enhance transdermal drug delivery for pathological scars. Verapamil is among the pharmacological agents evaluated in these combination protocols.11PubMed Central. Energy-based devices for enhanced transdermal drug delivery in pathological scars: A review
The logic is straightforward: if the drug works when it reaches the target tissue but struggles to get there through intact skin, then making the skin temporarily more permeable should improve results. Fractional ablative lasers create columns of microscopic wounds that heal within days but, while open, allow topical agents to pass through the stratum corneum directly. Early reports of laser-assisted verapamil delivery for keloids and burn scars are promising enough that the combination approach is showing up in clinical practice, though large randomized trials comparing it head-to-head with injection-based verapamil therapy are still lacking.
For patients who dread the pain of intralesional injections, which can be considerable in dense scar tissue, the combination of a fractional laser session followed by topical verapamil could offer a more tolerable treatment experience. The laser component carries its own risks, including temporary redness, swelling, and the possibility of post-inflammatory pigmentation changes in darker skin tones, so it is not a cost-free upgrade. But the concept of bypassing the skin barrier rather than just hoping the drug leaks through on its own represents a real advance in how topical verapamil might be used going forward.
Safety and Systemic Absorption
Verapamil taken by mouth is a potent cardiovascular drug. It slows the heart rate, lowers blood pressure, and relaxes blood vessels. The natural concern with any topical formulation is whether enough drug gets absorbed through the skin to cause those systemic effects.
For a single application, the answer appears to be no. A study of topical verapamil applied to the eye (at 0.25% concentration) found no detectable effect on heart rate or blood pressure after a single dose. However, after two weeks of daily application, significant reductions in both heart rate and blood pressure were observed.12PubMed. Topical verapamil and episcleral venous pressure That study involved ocular application, where drug absorption differs from skin application, but it establishes an important principle: repeated topical verapamil use can lead to measurable systemic drug levels over time.
The penile gel study mentioned earlier found verapamil in the urine after skin application, confirming that at least some drug does enter the bloodstream even when applied to ordinary skin.13Journal of Urology. Transdermal Application of Verapamil Gel to the Penile Shaft Fails to Infiltrate the Tunica Albuginea The amounts were small, and for most healthy adults, the cardiovascular impact of typical topical use is likely minimal. But if you are already taking medications that lower blood pressure or slow the heart rate, or if you have a heart rhythm condition, it is worth flagging topical verapamil use with your doctor. The systemic absorption is low, but “low” is not “zero,” especially with daily use over weeks or months.
Local side effects are generally mild. Some patients report skin irritation, redness, or itching at the application site. Allergic contact dermatitis to calcium channel blockers has been documented, though it is uncommon. If you develop a persistent rash at the application site that worsens rather than improves with continued use, that suggests a contact allergy rather than simple irritation, and you should stop applying the product.
What Topical Verapamil Cannot Do
The marketing around topical verapamil, particularly for Peyronie’s disease, tends to outrun the science. Products are sold online with confident claims about plaque reduction and curvature correction, sometimes at substantial cost. The penetration data for Peyronie’s disease specifically should give any prospective buyer pause: the evidence that the drug reaches its target in that condition is weak, regardless of what the pilot study on curvature improvement showed.
For scar treatment, the situation is more encouraging but still has limits. Topical verapamil is not a replacement for surgical excision of large keloids. It works best as a preventive measure during wound healing or as part of a multimodal approach to existing scars, not as a standalone cure for established, bulky scar tissue. Its role is closer to an adjunct, something that improves outcomes when combined with silicone sheeting, compression, or laser therapy, rather than a treatment you would rely on alone for severe scarring.
It is also worth understanding that not all scars respond equally. Keloids and hypertrophic scars are the primary targets for topical verapamil. Ordinary flat scars, stretch marks, and acne scars involve different pathology, and the evidence for verapamil’s benefit in those conditions is either absent or extremely preliminary. If you are considering topical verapamil, matching the product to the right type of scar matters.
How Topical Verapamil Compares with Injected Verapamil
Intralesional injection, where verapamil is injected directly into the scar or plaque with a needle, bypasses the skin barrier entirely and delivers a known concentration of drug straight to the target tissue. For keloids, intralesional verapamil has a longer track record and more consistent evidence than topical formulations. The systematic review of verapamil for keloids and hypertrophic scars included both injection and topical studies, and the pooled conclusion that verapamil performs comparably to corticosteroid injections draws more heavily on injection data than on topical data.14PubMed Central. Role of verapamil in preventing and treating hypertrophic scars and keloids
The tradeoff is comfort and convenience. Injecting into a keloid is painful, often requiring local anesthesia, and the procedure needs to be repeated every few weeks. Topical application is painless and can be done at home. For mild or moderate hypertrophic scars, especially those caught early, a topical approach may be sufficient. For large or long-standing keloids, injection is more likely to deliver meaningful results.
For Peyronie’s disease, the American Urological Association’s position has been more favorable toward intralesional injection than topical application, partly because of the penetration concerns described earlier. Intralesional verapamil for Peyronie’s has shown stabilization and sometimes improvement of curvature in clinical series, though it has been largely superseded by collagenase clostridium histolyticum as the only FDA-approved injectable for that condition. Topical verapamil remains in a gray area: patients continue to buy it, some report benefit, and the pharmacokinetic evidence says it should not be working for that indication. That disconnect remains unresolved.
Availability and Practical Considerations
Topical verapamil is not an FDA-approved product for any dermatologic or urologic indication. It exists in a regulatory gray zone. Compounding pharmacies prepare it on a prescription basis, and several online vendors sell verapamil gels marketed specifically for Peyronie’s disease or scar management. The concentration, vehicle, and excipients vary from one product to another, and because these are compounded preparations rather than FDA-reviewed drugs, there is no standardized formulation.
If your dermatologist or surgeon recommends topical verapamil as part of a scar-management plan, a compounding pharmacy can prepare it at the concentration they specify. Typical concentrations in the literature range from 5% to 15% for gel formulations, though the study that demonstrated scar-modulating effects after plastic surgery used a 50-micromolar concentration, which is considerably lower and reflects a different dosing philosophy.15PubMed. Topical verapamil as a scar modulator Asking your prescriber why they chose a particular concentration and how it compares with the published evidence is a reasonable conversation to have.
Cost varies widely. Compounded preparations can run anywhere from moderate to expensive depending on the pharmacy and the formulation complexity. Online Peyronie’s disease products tend to be priced at a premium. Insurance rarely covers compounded topical verapamil because it lacks FDA approval for these uses, so the expense typically comes out of pocket. Given the unresolved questions about penetration and efficacy, particularly for Peyronie’s, it is worth weighing that cost against the strength of the evidence before committing to months of treatment.